Cynata Therapeutics Limited, together with its subsidiaries, develops and commercializes a proprietary mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia.
+ 1 more risk
Exceptional growth potential with adequate balance sheet.
Share Price & News
How has Cynata Therapeutics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 51S's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: 51S underperformed the German Biotechs industry which returned -8.1% over the past year.
Return vs Market: 51S underperformed the German Market which returned -17.5% over the past year.
Price Volatility Vs. Market
How volatile is Cynata Therapeutics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Cynata Therapeutics undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: 51S (€0.34) is trading below our estimate of fair value (€7.23)
Significantly Below Fair Value: 51S is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: 51S is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: 51S is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 51S's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 51S is overvalued based on its PB Ratio (7.6x) compared to the DE Biotechs industry average (3.6x).
How is Cynata Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 51S is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (-0.4%).
Earnings vs Market: 51S is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: 51S's is expected to become profitable in the next 3 years.
Revenue vs Market: 51S's revenue (65.6% per year) is forecast to grow faster than the German market (4.1% per year).
High Growth Revenue: 51S's revenue (65.6% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 51S's Return on Equity is forecast to be high in 3 years time (35.2%)
How has Cynata Therapeutics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 51S is currently unprofitable.
Growing Profit Margin: 51S is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: 51S is unprofitable, and losses have increased over the past 5 years at a rate of -17.2% per year.
Accelerating Growth: Unable to compare 51S's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 51S is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (8.7%).
Return on Equity
High ROE: 51S has a negative Return on Equity (-82.59%), as it is currently unprofitable.
How is Cynata Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: 51S's short term assets (A$6.2M) exceed its short term liabilities (A$1.1M).
Long Term Liabilities: 51S has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: 51S is debt free.
Reducing Debt: 51S has no debt compared to 5 years ago when its debt to equity ratio was 0%.
Inventory Level: 51S has a low level of unsold assets or inventory.
Debt Coverage by Assets: Insufficient data to determine if 51S's debt is covered by short term assets.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 51S has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if 51S has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Cynata Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 51S's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate 51S's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 51S's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 51S's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 51S's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Ross MacDonald (61yo)
Dr. Ross Alexander MacDonald, Ph.D. serves as Member of Investment Committee at Uniseed Pty Limited and also serves as the Chief Executive Officer and Managing Director at Cynata Therapeutics Limited (form ...
CEO Compensation Analysis
Compensation vs Market: Ross's total compensation ($USD293.76K) is below average for companies of similar size in the German market ($USD431.45K).
Compensation vs Earnings: Ross's compensation has been consistent with company performance over the past year.
|MD, CEO & Executive Director||no data||AU$476.92k||2.49% A$1.0m|
|Company Secretary & Non-Executive Director||7.83yrs||AU$100.42k||0.33% A$137.0k|
|Independent Non-Executive Director||0.83yr||AU$52.27k||no data|
|Non-Executive Chairman||3yrs||AU$172.17k||0.17% A$70.7k|
|Non-Executive Director||6.58yrs||AU$50.42k||2.45% A$1.0m|
|Member of Scientific Advisory Board||no data||no data||no data|
Experienced Board: 51S's board of directors are considered experienced (6.6 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 7.4%.
Cynata Therapeutics Limited's company bio, employee growth, exchange listings and data sources
- Name: Cynata Therapeutics Limited
- Ticker: 51S
- Exchange: DB
- Founded: 2011
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: AU$74.173m
- Listing Market Cap: AU$41.411m
- Shares outstanding: 103.02m
- Website: https://www.cynata.com
- Cynata Therapeutics Limited
- 62 Lygon Street
- Level 3
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|CYP||ASX (Australian Securities Exchange)||Yes||Ordinary Shares||AU||AUD||Dec 2007|
|CYP||CHIA (Chi-X Australia)||Yes||Ordinary Shares||AU||AUD||Dec 2007|
|CYYN.F||OTCPK (Pink Sheets LLC)||Yes||Ordinary Shares||US||USD||Dec 2007|
|51S||DB (Deutsche Boerse AG)||Yes||Ordinary Shares||DE||EUR||Dec 2007|
Cynata Therapeutics Limited, together with its subsidiaries, develops and commercializes a proprietary mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. Its lead therapeutic product candidate is CYP-001, which has completed Phase I clinical trial for the treatment of graft versus host disease. The company also develops products for the treatment of heart attack, asthma, acute respiratory distress syndrome, diabetic wounds, coronary artery disease, brain cancer, and critical limb ischaemia, which are in preclinical model. The company has a partnership with Monash University, Critical Care Research Group, University of Sydney, Department of Neurosurgery at Brigham and Women's Hospital - Harvard Medical School, the Cooperative Research Centre for Cell Therapy Manufacturing, University of New South Wales, and the Royal College of Surgeons Ireland to develop stem cell therapies. It also has a strategic partnership with Fujifilm Corporation of Japan for the development and research of Cymerus technology. The company was formerly known as Eco Quest Limited and changed its name to Cynata Therapeutics Limited in October 2013. Cynata Therapeutics Limited was founded in 2011 and is based in Carlton, Australia.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/03/31 00:02|
|End of Day Share Price||2020/03/30 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.